<DOC>
	<DOC>NCT00272805</DOC>
	<brief_summary>The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (Coreg) twice a day.</brief_summary>
	<brief_title>Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg</brief_title>
	<detailed_description>Study Further Study Details: Primary outcome: pill-taking compliance (total doses taken versus total doses prescribed) Expected Total Enrollment: 400 subjects at 56 study sites in the U.S. Study Start: October 2005 This is a 5-month double-blind treatment study of male and female subjects with stable mild-to-severe chronic heart failure and with left ventricular dysfunction with symptoms of heart failure. Eligibility: Must be stable on treatment with Coreg IR at a standard dose: 6.25, 12.5, 25 mg twice a day.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction, Left</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Ability to read English Stable symptoms of mild to severe heart failure Stable medical regimen for heart failure On a stable dose of Coreg for at least 2 months LVEF ≤40% within the previous 24 months Uncorrected obstructive or regurgitant valve disease Complex congenital heart disease Recent ICD or pacemaker placement Recent coronary artery bypass surgery or stroke Candidate for heart transplanct within 5 months of study start Present or planned use of MAO inhibitors, alfphablockers, combined alphabeta blockers, any Class I/II antiarrythmnic agents, (amiodarone may be used if ≤ 200mg/day). Use of intravenous vasodilator/inotropic agents.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>left ventricular systolic dysfunction</keyword>
</DOC>